FindTrial
Sign In

A randomized phase III trial of S-1 versus S-1 plus irinotecan in advanced gastric cancer.

A randomized phase III trial of S-1 versus S-1 plus irinotecan in advanced gastric cancer.

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1080220081
Enrollment
Unknown
Registered
2005-09-09
Start date
2005-09-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced gastric cancer

Interventions

investigational material(s) Generic name etc : Irinotecan and S-1 INN of investigational material : Therapeutic category code : 424 Antineoplastic preparations extracted from plants Dosage and Admini

Sponsors

Yakult Honsha Co., Ltd. ,DAIICHI SANKYO Co.,Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Histologically confirmed unresectable or relapsed gastric cancer Neither prior chemotherapy nor prior radiotherapy Age between 20 and 75 years old ECOG Performance Status: 0-2

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Overall survival—

Contacts

Public Contact; ;

Yakult Honsha Co., Ltd.;DAIICHI SANKYO Co., Ltd.

;;

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026